🏛️ Verified NIH Record • Updated 2026-03-18
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (NCT03037164)
A Randomized, Double-Blind, Controlled, Parallel Group Study With the INTERCEPT Blood System for Red Blood Cells in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS)
🔵 Active, Not Recruiting Phase3 ⚙️ Medical Device Protocol Sponsor: Cerus Corporation
🩺 Plain-English Summary (8th-Grade Level)
To evaluate the safety and efficacy of red blood cells (RBCs) prepared with the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBCs in patients who require RBC transfusion support.
Who can join: Review the eligibility criteria below.
Location: Phoenix Children's Hospital (PCH) — Phoenix, Arizona
Age range: 4 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- Phoenix Children's Hospital (PCH) — Phoenix, Arizona
- Yale University — New Haven, Connecticut
- Mayo Clinic Jacksonville — Jacksonville, Florida
- Grady Health System — Atlanta, Georgia
- CHOA (Children's Healthcare of Atlanta) — Atlanta, Georgia
- University of Maryland School of Medicine — Baltimore, Maryland
- C4TKs (Cure 4 The Kids) — Las Vegas, Nevada
- St Jude Children's Research Hospital — Memphis, Tennessee
- UT Southwestern Medical Center — Dallas, Texas
- Baylor St. Luke's Medical Center — Houston, Texas
- Virginia Commonwealth University — Richmond, Virginia
- Versiti — Wauwatosa, Wisconsin
- Menonita General Hospital — Aibonito,
- HIMA San Pablo Hospital — Caguas,
- San Juan Bautista School of Medicine Clinical Research Unit — Caguas,
- Ege University Hospital — Izmir,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Anemia
- The Immediate and Long-term Effects of a Novel Marine-based Iron Supplement in Adult Females — Huntsville, Alabama
- INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders — Duarte, California
- Effects of Vitamin D and Marine Omega-3 Fatty Acids on Anemia — Boston, Massachusetts
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia — Birmingham, Alabama
- Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Birmingham, Alabama
Explore by condition: All Anemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.